Bicalutamide 50mg Tablet

Bicalutamide 50mg Tablet Hot flashes, breast swelling/tenderness/pain, nausea, vomiting, constipation, diarrhea, stomach upset, weight fluctuations, headache, difficulty sleeping, tiredness, or dizziness are all possible side effects. Tell your PCP or drug specialist immediately if these secondary effects persist or decline.

• Bicalutamide enhanced survival in patients with locally advanced disease compared to placebo after a median follow-up of 5.3 years (hazard ratio [HR], 0.68).
• Overall, the risk of disease progression was reduced by 43%, with the highest benefit shown in patients with locally advanced malignancies.

Bicalutamide 50mg Tablet significantly lowers the chance of PSA advancement, regardless of whether patients received standard care such as radical prostatectomy or radiation.

Bicalutamide is a drug that prevents testosterone from reaching cancer cells. Prostate cancer may shrink or cease growing if testosterone is not present.

Tumor flare-up reduction They may aggravate your symptoms during this period. This is known as tumor flare. If you’re taking bicalutamide to prevent tumor flare-ups, you’ll need to take it for a few days before starting the luteinizing hormone blocker, and you’ll need to take it for around 4 to 6 weeks.

In males with stage D2 metastatic prostate cancer (cancer that has spread), bicalutamide is combined with a luteinizing hormone-releasing hormone (LHRH) analog (ie, goserelin or leuprolide). Antiandrogens are a class of drugs that includes bicalutamide.

Bicalutamide 50mg Tablet is used in combination with other medications (GnRH agonists such as leuprolide or goserelin) to treat metastatic prostate cancer (cancer that starts in the prostate and has spread to other parts of the body). Bicalutamide has a place in the nonsteroidal antiandrogens class of medications.

Check this  Anti cancer Product Bicalutaz 50mg Tablet or you may explore more Anti cancer by clicking here 

We are an exporter from India and work in excess countries like the UAE, Oman, Qatar, Myanmar, Saudi Arabia, Netherlands, Albania, Saint Lucia, Jordan, Romania, South Africa, etc.